--- title: "NUEVOLUTION A/S – CVR 26029708, financials and ownership" description: "NUEVOLUTION A/S (CVR 26029708): NUEVOLUTION A/S develops drug candidates for cancer, inflammatory and cardiometabolic diseases, and created the Chemetics platform for discovering small-molecule drug candidates. Revenue rose from DKK 118.4 million in 2024 to DKK 203.3 million in 2025, while operating performance turned from a DKK 26.9 million loss to a DKK 44.8 million profit; the annual report attributes the improvement to a licensing fee and higher contract-work activity. In August 2026, the company had 100 employees and 83 full-time equivalents (FTE). Amgen, Inc. of the United States has directly owned the company, with 100% of its capital and voting rights, since 15 November 2023; previously, Nuevolution AB of Sweden owned 100% from 13 November 2015 to 15 November 2023." canonical_url: "https://datapublica.dk/en/companies/26029708-nuevolution-a-s" locale: "en" route_type: "company_overview" robots: "index,follow" --- # NUEVOLUTION A/S NUEVOLUTION A/S \(CVR 26029708\): NUEVOLUTION A/S develops drug candidates for cancer, inflammatory and cardiometabolic diseases, and created the Chemetics platform for discovering small-molecule drug candidates. Revenue rose from DKK 118.4 million in 2024 to DKK 203.3 million in 2025, while operating performance turned from a DKK 26.9 million loss to a DKK 44.8 million profit; the annual report attributes the improvement to a licensing fee and higher contract-work activity. In August 2026, the company had 100 employees and 83 full-time equivalents \(FTE\). Amgen, Inc. of the United States has directly owned the company, with 100% of its capital and voting rights, since 15 November 2023; previously, Nuevolution AB of Sweden owned 100% from 13 November 2015 to 15 November 2023. CVR number: 26029708 ## Company details - **CVR number:** 26029708 - **Status:** Aktiv - **Address:** Rønnegade 8 5, 2100, København Ø - **Legal form:** Aktieselskab \(A/S\) - **Founded:** May 8, 2001 - **Employees / FTEs:** 100 / 83 - **Production units:** 2 ## Description NUEVOLUTION A/S develops drug candidates for cancer, inflammatory and cardiometabolic diseases, and created the Chemetics platform for discovering small-molecule drug candidates. Revenue rose from DKK 118.4 million in 2024 to DKK 203.3 million in 2025, while operating performance turned from a DKK 26.9 million loss to a DKK 44.8 million profit; the annual report attributes the improvement to a licensing fee and higher contract-work activity. In August 2026, the company had 100 employees and 83 full-time equivalents \(FTE\). [Amgen, Inc.](https://datapublica.dk/en/participants/pid_owner_enhed_4009961697-amgen-inc) of the United States has directly owned the company, with 100% of its capital and voting rights, since 15 November 2023; previously, [Nuevolution AB](https://datapublica.dk/en/participants/pid_owner_enhed_4006334276-nuevolution-ab) of Sweden owned 100% from 13 November 2015 to 15 November 2023. ### Company's own description on virk.dk Company and research and development activitiesNuevolution A/S is a Danish biopharmaceutical company focused on developing drug treatments for human disease within oncology, inflammatory diseases and cardiometabolic diseases.Nuevolution A/S is the inventor of Chemetics, a drug discovery platform, which enables efficient discovery of novel small molecule \(tablet based\) drug candidates.The Chemetics platform provides access to screening of trillions of molecules and efficient optimization of drug properties in the process of identifying the drug candidate.Our efforts are leveraged by a proven and highly efficient drug discovery engine, and backed by a skilled and dedicated team of employees, world-class academic and corporate expert advisers catalyzing our ambition to deliver new medicines to patients. ## Analysis by AI ✨ NUEVOLUTION A/S increased revenue from DKK 118.4 million in 2024 to DKK 203.3 million in 2025, moving from an operating loss of DKK 26.9 million to an operating profit of DKK 44.8 million. The annual report attributes the development to a licensing fee and higher contract-work activity. The workforce grew from 95 employees and 81 FTE in September 2025 to 100 employees and 83 FTE in August 2026. [Amgen, Inc.](https://datapublica.dk/en/participants/pid_owner_enhed_4009961697-amgen-inc) in the United States has been NUEVOLUTION A/S’ direct owner, holding 100% of its capital and voting rights, since 15 November 2023. Before that, [Nuevolution AB](https://datapublica.dk/en/participants/pid_owner_enhed_4006334276-nuevolution-ab) in Sweden owned 100% of the company from 13 November 2015 to 15 November 2023. AI-generated texts are based on registered information, which may be delayed or incomplete. Errors may occur. ## Activities and industry - Forskning og eksperimentel udvikling inden for naturvidenskab og teknik - 721000 — Forskning og eksperimentel udvikling inden for naturvidenskab og teknik ## Latest financial period - **Reporting period:** 2025 - **Currency:** DKK - **Revenue:** 203,323,000 - **Operating profit:** 44,773,000 - **Profit after tax:** 39,754,000 - **Assets:** 238,040,000 - **Equity:** 89,493,000 ## People | Person | Roles | Titles | | --- | --- | --- | | [Tore von Würden Petersen](https://datapublica.dk/en/people/pid_entity_4008066734-tore-von-w-rden-petersen) | Board | FORMAND | | [Thomas Franch](https://datapublica.dk/en/people/pid_entity_4004052160-thomas-franch) | Management | DIREKTØR | ## Auditor | Audit firm | Auditor | Role | From | | --- | --- | --- | --- | | EY Godkendt Revisionspartnerselskab | Hans B. Vistisen | State AuthorisedPublic Accountant | Jun 29, 2026 | | EY Godkendt Revisionspartnerselskab | Mads Obel Knøsgaard | State AuthorisedPublic Accountant | Jun 29, 2026 | ## Legal owners ### Current | Owner | Ownership | Voting rights | From | | --- | --- | --- | --- | | OwnerAmgen, Inc. | Ownership100 % | Voting rights100 % | FromNov 15, 2023 | ### Previous | Owner | Ownership | Voting rights | From | To | | --- | --- | --- | --- | --- | | OwnerNuevolution AB | Ownership100 % | Voting rights100 % | FromNov 13, 2015 | ToNov 15, 2023 | | OwnerSEB Venture Capital, a unit within Skandinaviska Enskilda Banken AB \(publ\) | Ownership25–33.32 % | Voting rights25 % | FromMar 23, 2015 | ToNov 12, 2015 | | OwnerSUNSTONE LIFE SCIENCE VENTURES FUND I K/S | Ownership25–33.32 % | Voting rights25 % | FromMar 23, 2015 | ToNov 12, 2015 | | OwnerStiftelsen Industrifonden | Ownership20–24.99 % | Voting rights20 % | FromMar 23, 2015 | ToNov 12, 2015 | | OwnerS-E-Bankens Utvecklingsstiftelse | Ownership10–14.99 % | Voting rights10 % | FromMar 23, 2015 | ToNov 12, 2015 | ## Ultimate owners [View ownership diagram](https://datapublica.dk/en/companies/26029708-nuevolution-a-s/portfolio) | Name | Ownership through | Calculated ownership | | --- | --- | --- | | Amgen, Inc. | Direct | 100 % | ## Company pages - [Overview](https://datapublica.dk/en/companies/26029708-nuevolution-a-s) - [Financial report](https://datapublica.dk/en/companies/26029708-nuevolution-a-s/financials) - [Risk](https://datapublica.dk/en/companies/26029708-nuevolution-a-s/risk) - [Timeline](https://datapublica.dk/en/companies/26029708-nuevolution-a-s/timeline) - [Ownership and relations](https://datapublica.dk/en/companies/26029708-nuevolution-a-s/portfolio) - [Production units](https://datapublica.dk/en/companies/26029708-nuevolution-a-s/production-units) - [Gazelle](https://datapublica.dk/en/companies/26029708-nuevolution-a-s/gazelle) - [Investments](https://datapublica.dk/en/companies/26029708-nuevolution-a-s/investments) ## Official sources - [Official CVR record on Virk](https://datacvr.virk.dk/enhed/virksomhed/26029708)